Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ £¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

ÃÀ¸ß÷µÄÒ©ÎïתÔËÌåÑо¿Ð§ÀÍ

2016-08-11
|
»á¼ûÁ¿£º

Ò©ÎïתÔËÌåÊÇλÓÚϸ°ûĤÉϵÄÖ÷ÒªµÄ¹¦Ð§ÐÔĤÂѰ×£¬ £¬£¬£¬£¬£¬ÊÇÒ©Îï¿çϸ°ûĤתÔ˵ÄÔØÌ壬 £¬£¬£¬£¬£¬ÔÚÒ©ÎïÎüÊÕ,ÂþÑÜ,´úл¼°ÉøÍ¸µÈÒ©´ú¶¯Á¦Ñ§Àú³ÌÖÐʩչÖ÷Òª×÷Óà ¡£¡£¡£¡£¡£Õؽ¨Ö®³õ£¬ £¬£¬£¬£¬£¬ÃÀ¸ß÷¼´×¢ÖØ´òÔìһվʽЧÀÍ£¬ £¬£¬£¬£¬£¬ÖÂÁ¦ÓÚΪ¿Í»§½ÚԼʱ¼ä±¾Ç®£¬ £¬£¬£¬£¬£¬Ìá¸ßÏàͬЧÂʽø¶ø¼ÓËÙÐÂÒ©Ñз¢Àú³Ì£»£»£»£»£»£»ÏÖÔÚ£¬ £¬£¬£¬£¬£¬ÔÚÒ»Ö±ÍêÉÆÒ»Õ¾Ê½Ð§À͵Äͬʱ£¬ £¬£¬£¬£¬£¬ÃÀ¸ß÷DZÐÄרעµÄÒ»Ö±ÌáÉýƽ̨רҵˮƽ£¬ £¬£¬£¬£¬£¬ÒÔÆÚΪ¿Í»§ÌṩÖÜȫϸ»¯£¬ £¬£¬£¬£¬£¬Ô½·¢¾«×¼ÉîÈëµÄЧÀÍ ¡£¡£¡£¡£¡£Ò©ÎïתÔËÌåµÄÑо¿×÷ΪÃÀ¸ß÷ϸ»¯Ð§ÀÍϵͳÖеÄÒ»Ïî³ÉÊì¼¼Êõ¿ÉÒÔΪÐÂÒ©Éè¼Æ¡¢Ìá¸ßÒ©Îï°ÐÏòÐÔ¼°Ò©ÎïÏ໥×÷ÓõÈÑо¿Ìṩ¿É¿¿ÒÀ¾Ý ¡£¡£¡£¡£¡£

CFDA¡¶Ò©Îï·ÇÁÙ´²Ò©´ú¶¯Á¦Ñ§Ñо¿¼¼ÊõÖ¸µ¼Ô­Ôò¡·ÓëFDA¡¶Ò©ÎïÏ໥×÷ÓÃÑо¿¼¼ÊõÖ¸µ¼Ô­Ôò(²Ý°¸)(Drug Interaction Studies¡ªStudy Design,Data Analysis, and Implications for Dosing and Labeling Recommendations Draft Guidance for Industry)¹«²¼ÒÔÀ´£¬ £¬£¬£¬£¬£¬ÆßÖÖ¾ßÓÐÖ÷ÒªÁÙ´²ÒâÒåµÄÍâÅźÍÉãÈëתÔËÌ壨P-gp¡¢BCRP¡¢OATP1B1¡¢OATP13¡¢OAT1¡¢OAT3ºÍOCT2£©ÔÚÒ©´ú¶¯Á¦Ñ§Àú³ÌÖеÄ×÷ÓÃÕýÈÕÒæ³ÉΪÁ¢ÒìÐÂÒ©ÎïÑо¿ÓëÉ걨µÄ±Ø±¸Ñо¿ÏîÄ¿ ¡£¡£¡£¡£¡£ÃÀ¸ß÷ҩÎïתÔËÌåÑо¿ÍŶÓÒµÒѽ¨Éè¶ÔÕâЩÖ÷ҪתÔËÌåµÄ³ÉÊìÌåÍâÑо¿¼¼Êõ ¡£¡£¡£¡£¡£Í¨¹ý¹¹½¨¸üÎȹ̵ÄÌåÍâϸ°ûÄ£×Ó²¢¾ÙÐиüÑϽ÷µÄÑéÖ¤£¬ £¬£¬£¬£¬£¬ÃÀ¸ß÷½«¸ü׼ȷ¡¢¸ü¿ìËÙµÄΪҵ½çͬÈÊÌṩÓÅÖʵÄתÔËÌåÑо¿Ð§ÀÍ ¡£¡£¡£¡£¡£

Ò©ÎïתÔËÌåÔÚÒ©ÎïÎüÊÕ¡¢ÂþÑÜ¡¢´úл¡¢ÉøÍ¸ÖеÄ×÷ÓÃ

¡øÒ©ÎïתÔËÌåÔÚÒ©ÎïÎüÊÕ¡¢ÂþÑÜ¡¢´úл¡¢ÉøÍ¸ÖеÄ×÷ÓÃ

ʲôÊÇÒ©ÎïתÔËÌ壿£¿£¿£¿£¿

Ò©ÎïתÔËÌåÊÇһϵÁб£´æÓÚϸ°ûĤÍâò£¬ £¬£¬£¬£¬£¬¼ÌÐøÒ©Îï¿çĤתÔ˹¦Ð§µÄÂѰ×ÖʵÄ×Ü³Æ ¡£¡£¡£¡£¡£ËüÃǼÓÈëÒ©Îï½øÈëÉúÎïÌåµÄÎüÊÕÀú³Ì£¬ £¬£¬£¬£¬£¬µ÷¿ØÒ©Îï´©Ô½ÉúÎïÆÁÕϵÄÌåÄÚÂþÑÜÀú³Ì£¬ £¬£¬£¬£¬£¬×îÖս鵼¸ÎÔàºÍÉöÔà¶ÔÒ©Îï¼°Æä´úл²úÆ·µÄÉøÍ¸ ¡£¡£¡£¡£¡£´ó´ó¶¼µÍÖ¬ÈÜÐÔ¡¢Ð¡·Ö×ÓÁ¿µÄÒ©Î £¬£¬£¬£¬£¬Æä·Ö×ÓÒòËØ¿Éͨ¹ý´¿´âÀ©É¢ÐÎʽ͸Ï꾡°ûµÄË«²ãÁ×֬Ĥ£¬ £¬£¬£¬£¬£¬¶øÖ¬ÈÜÐԵ͡¢·Ö×ÓÁ¿½Ï´óµÄ¼«ÐÔÒ©Î £¬£¬£¬£¬£¬Í¨³£ÒÔתÔËÌåΪǰÑÔʵÏÖ¿çϸ°ûĤתÔË ¡£¡£¡£¡£¡£

Ò©ÎïתÔËÌåµÄÁ½´óÀàÐÍ

¡øÒ©ÎïתÔËÌåµÄÁ½´óÀàÐÍ

Ò©ÎïתÔËÌåµÄÖÖÀà

ÈËÌåÄÚ¼ÓÈëÒ©Îï¿çĤµÄתÔËÌåÖÖÀàÖڶ࣬ £¬£¬£¬£¬£¬°´¿çĤתÔËÆ«Ïò¿É·ÖΪÉãÈëºÍÍâÅÅÁ½´óÀà ¡£¡£¡£¡£¡£½éµ¼Ò©Îï½øÈëϸ°ûµÄÉãÈëתÔËÌåÊôÓÚÈÜÖÊÔØÌåÂѰ×(solute carrier,SLC)¼Ò×壬 £¬£¬£¬£¬£¬Ö÷Òª°üÀ¨°±»ùËáתÔËÌå(L-type amino transporter, LAT)¡¢ÄÆÒÀÀµÐÔÐø·¢ÐÔ×Ô¶¯×ªÔËÌå (sodium dependent secondary activetransporters, SGLTs)¡¢ÓлúÒõÀë×Ó (organic anion transporters, OATs)¼°ÑôÀë×ÓתÔËÌå(organic cation transporters, OCTs)µÈ ¡£¡£¡£¡£¡£ÍâÅÅתÔËÌåÔòÊôÓÚATPÁ¬ÏµºÐתÔËÌå (ATP binding cassette, ABC) ¼Ò×壬 £¬£¬£¬£¬£¬¿ÉʹÓÃË®½âATP µÄÄÜÁ¿¶ÔÒ©Îï¼°ÄÚÔ´ÐÔÎïÖʾÙÐÐתÔË£¬ £¬£¬£¬£¬£¬Ö÷Òª°üÀ¨P-ÌÇÂѰ×(P-glycoprotein, P-gp)¡¢¶àÒ©ÄÍÒ©Ïà¹ØÂÑ°× (multidrugresistance associated proteins, MRPs)¡¢ÈéÏÙ°©ÄÍÒ©ÂÑ°× (breast cancerresistance protein, BCRP) ¼°µ¨ËáÑÎÍâÅűÃ(bile salt export pump, BSEP)µÈ ¡£¡£¡£¡£¡£

Ò©ÎïתÔËÌåµÄÓ¦ÓÃ

תÔËÌåÔÚÒ©ÎïÎüÊÕ¡¢ÂþÑÜ¡¢´úл¼°ÉøÍ¸µÄ¶¯Á¦Ñ§Àú³ÌÖÐʩչÖ÷Òª×÷Ó㬠£¬£¬£¬£¬£¬Òò´ËÆä¹¦Ð§È±Ê§»òÒÖÖÆÊÇÒýÆðÒ©ÎïÏ໥×÷Óü°Ä³Ð©¼²²¡µÄÖ÷ÒªÔµ¹ÊÔ­ÓÉ ¡£¡£¡£¡£¡£ÏÖÔÚÐí¶àÒ©ÎïÒѱ»Ö¤ÊµÊÇתÔËÌåµÄµ×Îï»òÒÖÖÆ¼Á£¬ £¬£¬£¬£¬£¬Èç¶àÖÖ¿¹Ö×ÁöÒ©¡¢¿¹ÉúËØ¡¢Ç¿ÐÄÜÕÀà¡¢¸ÆÞ׿¹¼Á¡¢HIVÂѰ×øÒÖÖÆ¼Á¡¢ÃâÒßÒÖÖÆ¼ÁµÈµÄÌåÄÚÒ©¶¯Ñ§Àú³Ì¾ùÉæ¼°ÌØÒìµÄ»ò·ÇÌØÒìµÄתÔËÌå ¡£¡£¡£¡£¡£×ªÔËÌåÑо¿¶ÔÆÊÎöÒ©´ú¶¯Á¦Ñ§ÌØÕ÷¡¢Ò©Ð§Ñ§¼°¶¾ÐÔ¾ù¾ßÓÐÖ÷Òª×÷Óà ¡£¡£¡£¡£¡£ÔÚÒ©ÎïÑз¢ÔçÆÚ¾ÙÐÐÒ©ÎïתÔËÌåÑо¿£¬ £¬£¬£¬£¬£¬¿ÉÒÔ¶Ô»¯ºÏÎïÔÚÈËÌåÄÚµÄÒ©´ú¶¯Á¦Ñ§²ÎÊý¾ÙÐÐÔçÆÚÕ¹Íû£¬ £¬£¬£¬£¬£¬¹ØÓÚÌá¸ßÁ¢ÒìÒ©ÎïµÄÑз¢Ð§ÂʾßÓÐÖ÷ÒªµÄÒâÒå ¡£¡£¡£¡£¡£

ÃÀ¸ß÷ÊǽÏÔçÔÚÖйú¿ªÕ¹Ò©Îï´úл¶¯Á¦Ñ§Ð§À͵ÄCRO¹«Ë¾Ö®Ò»£¬ £¬£¬£¬£¬£¬Ð§ÀÍÁìÓòº­¸Ç´úлÎȹÌÐÔ¡¢P450øÒÖÖÆ¡¢P450øÓÕµ¼¡¢Ã¸±íÐÍÆÊÎö¡¢ÂѰ×Á¬ÏµÂÊ¡¢ºìϸ°û/Ѫ½¬·ÖÅɱȡ¢Caco-2ÉøÍ¸ÐÔ¡¢×ªÔËÌåÑо¿¡¢´úл²úÆ·Åжϡ¢·´Ó¦ÐÔ´úл²úƷɸ²é¡¢ÖÖÖÖÊô¶à;¾¶¸øÒ©PK¡¢×éÖ¯ÂþÑÜÓëѪÄÔÆÁÕÏͨ͸ÐÔ¡¢ÉøÍ¸Ñо¿¡¢ÌåÄÚÒ©ÎïÏ໥×÷ÓᢶàÖÜÆÚ½»Ö¯BE¡¢´¦·½É¸Ñ¡µÈ ¡£¡£¡£¡£¡£

ϸ»¯Ð§ÀÍÆ½Ì¨£¬ £¬£¬£¬£¬£¬ÓÅ»¯Ñз¢¼¼Êõ£¬ £¬£¬£¬£¬£¬ÍêÉÆÒ»Õ¾Ê½Ð§ÀÍ£¬ £¬£¬£¬£¬£¬ÃÀ¸ß÷׷Çó¸ü׿Խ£¬ £¬£¬£¬£¬£¬¸ü¾«×¼µÄÁÙ´²Ç°Ð§ÀÍ ¡£¡£¡£¡£¡£

Ö÷Òª²Î¿¼ÎÄÏ×

[1] CFDA Ò©Îï·ÇÁÙ´²Ò©´ú¶¯Á¦Ñ§Ñо¿¼¼ÊõÖ¸µ¼Ô­Ôò, 2015

[2] US FDGuidance for Industry£º Drug Interaction Studies¡ªStudy Design,Data Analysis, and Implications for Dosing and Labeling Recommendations £¨Draft Guidance£©£¬ £¬£¬£¬£¬£¬2012

[3] Àîñõ, Ê¢Àò, ÀîÑ࣬ £¬£¬£¬£¬£¬Ò©Ñ§Ñ§±¨,2014,49(7):963-970

ÁªÏµÃÀ¸ß÷£º
µç»°: +86 (21) 5859-1500£¨×Ü»ú£©
Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿